Reactions Weekly

April 2018, Volume 1697, Issue 1, pp 211–211 | Cite as

Ipilimumab/nivolumab/pembrolizumab

Various toxicities: 14 case reports

Case report

First Online: 14 April 2018

• 16 Downloads

This is a preview of subscription content, log in to check access.

Reference

1. Lidar M, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmunity Reviews 17: 284-289, No. 3, Mar 2018. Available from: URL: http://doi.org/10.1016/j.autrev.2018.01.003 - IsraelCrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018